Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma

Background The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded. Methods A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effect...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cancer research and clinical oncology 2024-05, Vol.150 (5), p.278-278, Article 278
Hauptverfasser: Mao, Xingjun, Huang, Wen, Xue, Qing, Zhang, Xiaolei
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 278
container_issue 5
container_start_page 278
container_title Journal of cancer research and clinical oncology
container_volume 150
creator Mao, Xingjun
Huang, Wen
Xue, Qing
Zhang, Xiaolei
description Background The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded. Methods A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effectuated using the E-MTAB-1980 dataset. The exploration of immune infiltration scores was undertaken through the exploitation of multiple algorithms. Single-cell RNA sequencing data were procured from the GSE171306 dataset. Real-time quantitative PCR (RT-qPCR) was engaged to scrutinize the differential expression of SLC25A37 across cancer and paracancer tissues, as well as diverse cell lines. Assessments of proliferative and metastatic alterations in 769-P and 786-O cells were accomplished through Cell Counting Kit-8 (CCK8) and wound healing assays. Results The necroptosis-related signature (NRS) emerges as a discerning metric, delineating patients’ immune attributes, tumor mutation burden, immunotherapy response, and drug susceptibility. Single-cell RNA sequencing analysis unveils the marked enrichment of SLC25A37 in tumor cells. Concurrently, RT-qPCR discloses the overexpression of SLC25A37 in both ccRCC tissues and cell lines. SLC25A37 knockdown mitigates the proliferative and metastatic propensities of 769-P and 786-O cells, as evidenced by CCK8 and wound healing assays. Conclusion The NRS assumes a pivotal role in ascertaining the prognosis, tumor mutation burden, immunotherapy response, drug susceptibility, and immune cell infiltration features of ccRCC patients. SLC25A37 emerges as a putative player in immunosuppressive microenvironments, thereby providing a prospective avenue for the design of innovative immunotherapeutic targets for ccRCC.
doi_str_mv 10.1007/s00432-024-05761-y
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11129999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3060564808</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-dc463a857ecf83871ba82e22b4c6ec47940b9abc4d28504016fa43a5d19b2ae3</originalsourceid><addsrcrecordid>eNp9kUtv1TAQhSNERUvhD7BAkdh0Exg_8lohVLWAVFEWd29NnMmtK8cOdlLpij-PL7n0waLeeOTzzRmPTpa9Y_CRAdSfIoAUvAAuCyjrihW7F9kJ2z8xIcqXj-rj7HWMtwCsLmv-KjsWTQNJhJPs98_gt87H2ejcjBPqOUfXp3JcnJ9vKOBEy0G0RuNsvIu5H_IfFxsfTSwCWZypz6cHn9H3ZHPjcm0JQ67J2jyQQ7uWGoM2zo_4Jjsa0EZ6e7hPs83lxeb8W3F1_fX7-ZerQouymotey0pgU9akh0Y0Neuw4cR5J3VFWtathK7FTsueNyVIYNWAUmDZs7bjSOI0-7zaTks3Uq_JzQGtmoIZMeyUR6OeKs7cqK2_U4wx3qaTHM4ODsH_WijOajRxvws68ktUAiqoZcslJPTDf-itX0LafaXKSjbQJIqvlA4-xkDD_W8YqH22as1WpWzV32zVLjW9f7zHfcu_MBMgViAmyW0pPMx-xvYPn7OzAA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3060564808</pqid></control><display><type>article</type><title>Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA/Free Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Mao, Xingjun ; Huang, Wen ; Xue, Qing ; Zhang, Xiaolei</creator><creatorcontrib>Mao, Xingjun ; Huang, Wen ; Xue, Qing ; Zhang, Xiaolei</creatorcontrib><description>Background The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded. Methods A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effectuated using the E-MTAB-1980 dataset. The exploration of immune infiltration scores was undertaken through the exploitation of multiple algorithms. Single-cell RNA sequencing data were procured from the GSE171306 dataset. Real-time quantitative PCR (RT-qPCR) was engaged to scrutinize the differential expression of SLC25A37 across cancer and paracancer tissues, as well as diverse cell lines. Assessments of proliferative and metastatic alterations in 769-P and 786-O cells were accomplished through Cell Counting Kit-8 (CCK8) and wound healing assays. Results The necroptosis-related signature (NRS) emerges as a discerning metric, delineating patients’ immune attributes, tumor mutation burden, immunotherapy response, and drug susceptibility. Single-cell RNA sequencing analysis unveils the marked enrichment of SLC25A37 in tumor cells. Concurrently, RT-qPCR discloses the overexpression of SLC25A37 in both ccRCC tissues and cell lines. SLC25A37 knockdown mitigates the proliferative and metastatic propensities of 769-P and 786-O cells, as evidenced by CCK8 and wound healing assays. Conclusion The NRS assumes a pivotal role in ascertaining the prognosis, tumor mutation burden, immunotherapy response, drug susceptibility, and immune cell infiltration features of ccRCC patients. SLC25A37 emerges as a putative player in immunosuppressive microenvironments, thereby providing a prospective avenue for the design of innovative immunotherapeutic targets for ccRCC.</description><identifier>ISSN: 1432-1335</identifier><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-024-05761-y</identifier><identifier>PMID: 38801430</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Algorithms ; Biomarkers, Tumor - genetics ; Cancer Research ; Carcinoma, Renal Cell - genetics ; Carcinoma, Renal Cell - immunology ; Carcinoma, Renal Cell - pathology ; Carcinoma, Renal Cell - therapy ; Cell Line, Tumor ; Cell Proliferation ; Clear cell-type renal cell carcinoma ; Gene Expression Regulation, Neoplastic ; Hematology ; Humans ; Immunotherapy ; Immunotherapy - methods ; Infiltration ; Internal Medicine ; Kidney cancer ; Kidney Neoplasms - genetics ; Kidney Neoplasms - immunology ; Kidney Neoplasms - pathology ; Medicine ; Medicine &amp; Public Health ; Metastases ; Metastasis ; Microenvironments ; Mutation ; Necroptosis ; Oncology ; Prognosis ; Sequence analysis ; Tumor cells ; Tumor Microenvironment - immunology ; Tumors ; Wound healing</subject><ispartof>Journal of cancer research and clinical oncology, 2024-05, Vol.150 (5), p.278-278, Article 278</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c356t-dc463a857ecf83871ba82e22b4c6ec47940b9abc4d28504016fa43a5d19b2ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-024-05761-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://doi.org/10.1007/s00432-024-05761-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,864,885,27923,27924,41119,41487,42188,42556,51318,51575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38801430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mao, Xingjun</creatorcontrib><creatorcontrib>Huang, Wen</creatorcontrib><creatorcontrib>Xue, Qing</creatorcontrib><creatorcontrib>Zhang, Xiaolei</creatorcontrib><title>Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Background The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded. Methods A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effectuated using the E-MTAB-1980 dataset. The exploration of immune infiltration scores was undertaken through the exploitation of multiple algorithms. Single-cell RNA sequencing data were procured from the GSE171306 dataset. Real-time quantitative PCR (RT-qPCR) was engaged to scrutinize the differential expression of SLC25A37 across cancer and paracancer tissues, as well as diverse cell lines. Assessments of proliferative and metastatic alterations in 769-P and 786-O cells were accomplished through Cell Counting Kit-8 (CCK8) and wound healing assays. Results The necroptosis-related signature (NRS) emerges as a discerning metric, delineating patients’ immune attributes, tumor mutation burden, immunotherapy response, and drug susceptibility. Single-cell RNA sequencing analysis unveils the marked enrichment of SLC25A37 in tumor cells. Concurrently, RT-qPCR discloses the overexpression of SLC25A37 in both ccRCC tissues and cell lines. SLC25A37 knockdown mitigates the proliferative and metastatic propensities of 769-P and 786-O cells, as evidenced by CCK8 and wound healing assays. Conclusion The NRS assumes a pivotal role in ascertaining the prognosis, tumor mutation burden, immunotherapy response, drug susceptibility, and immune cell infiltration features of ccRCC patients. SLC25A37 emerges as a putative player in immunosuppressive microenvironments, thereby providing a prospective avenue for the design of innovative immunotherapeutic targets for ccRCC.</description><subject>Algorithms</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cancer Research</subject><subject>Carcinoma, Renal Cell - genetics</subject><subject>Carcinoma, Renal Cell - immunology</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Carcinoma, Renal Cell - therapy</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Clear cell-type renal cell carcinoma</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Immunotherapy - methods</subject><subject>Infiltration</subject><subject>Internal Medicine</subject><subject>Kidney cancer</subject><subject>Kidney Neoplasms - genetics</subject><subject>Kidney Neoplasms - immunology</subject><subject>Kidney Neoplasms - pathology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Microenvironments</subject><subject>Mutation</subject><subject>Necroptosis</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Sequence analysis</subject><subject>Tumor cells</subject><subject>Tumor Microenvironment - immunology</subject><subject>Tumors</subject><subject>Wound healing</subject><issn>1432-1335</issn><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kUtv1TAQhSNERUvhD7BAkdh0Exg_8lohVLWAVFEWd29NnMmtK8cOdlLpij-PL7n0waLeeOTzzRmPTpa9Y_CRAdSfIoAUvAAuCyjrihW7F9kJ2z8xIcqXj-rj7HWMtwCsLmv-KjsWTQNJhJPs98_gt87H2ejcjBPqOUfXp3JcnJ9vKOBEy0G0RuNsvIu5H_IfFxsfTSwCWZypz6cHn9H3ZHPjcm0JQ67J2jyQQ7uWGoM2zo_4Jjsa0EZ6e7hPs83lxeb8W3F1_fX7-ZerQouymotey0pgU9akh0Y0Neuw4cR5J3VFWtathK7FTsueNyVIYNWAUmDZs7bjSOI0-7zaTks3Uq_JzQGtmoIZMeyUR6OeKs7cqK2_U4wx3qaTHM4ODsH_WijOajRxvws68ktUAiqoZcslJPTDf-itX0LafaXKSjbQJIqvlA4-xkDD_W8YqH22as1WpWzV32zVLjW9f7zHfcu_MBMgViAmyW0pPMx-xvYPn7OzAA</recordid><startdate>20240527</startdate><enddate>20240527</enddate><creator>Mao, Xingjun</creator><creator>Huang, Wen</creator><creator>Xue, Qing</creator><creator>Zhang, Xiaolei</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240527</creationdate><title>Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma</title><author>Mao, Xingjun ; Huang, Wen ; Xue, Qing ; Zhang, Xiaolei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-dc463a857ecf83871ba82e22b4c6ec47940b9abc4d28504016fa43a5d19b2ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Algorithms</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cancer Research</topic><topic>Carcinoma, Renal Cell - genetics</topic><topic>Carcinoma, Renal Cell - immunology</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Carcinoma, Renal Cell - therapy</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Clear cell-type renal cell carcinoma</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Immunotherapy - methods</topic><topic>Infiltration</topic><topic>Internal Medicine</topic><topic>Kidney cancer</topic><topic>Kidney Neoplasms - genetics</topic><topic>Kidney Neoplasms - immunology</topic><topic>Kidney Neoplasms - pathology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Microenvironments</topic><topic>Mutation</topic><topic>Necroptosis</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Sequence analysis</topic><topic>Tumor cells</topic><topic>Tumor Microenvironment - immunology</topic><topic>Tumors</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mao, Xingjun</creatorcontrib><creatorcontrib>Huang, Wen</creatorcontrib><creatorcontrib>Xue, Qing</creatorcontrib><creatorcontrib>Zhang, Xiaolei</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mao, Xingjun</au><au>Huang, Wen</au><au>Xue, Qing</au><au>Zhang, Xiaolei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2024-05-27</date><risdate>2024</risdate><volume>150</volume><issue>5</issue><spage>278</spage><epage>278</epage><pages>278-278</pages><artnum>278</artnum><issn>1432-1335</issn><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Background The ramifications of necroptosis on the prognostication of clear cell renal cell carcinoma (ccRCC) remain inadequately expounded. Methods A prognostic model delineating the facets of necroptosis in ccRCC was constructed, employing a compendium of algorithms. External validation was effectuated using the E-MTAB-1980 dataset. The exploration of immune infiltration scores was undertaken through the exploitation of multiple algorithms. Single-cell RNA sequencing data were procured from the GSE171306 dataset. Real-time quantitative PCR (RT-qPCR) was engaged to scrutinize the differential expression of SLC25A37 across cancer and paracancer tissues, as well as diverse cell lines. Assessments of proliferative and metastatic alterations in 769-P and 786-O cells were accomplished through Cell Counting Kit-8 (CCK8) and wound healing assays. Results The necroptosis-related signature (NRS) emerges as a discerning metric, delineating patients’ immune attributes, tumor mutation burden, immunotherapy response, and drug susceptibility. Single-cell RNA sequencing analysis unveils the marked enrichment of SLC25A37 in tumor cells. Concurrently, RT-qPCR discloses the overexpression of SLC25A37 in both ccRCC tissues and cell lines. SLC25A37 knockdown mitigates the proliferative and metastatic propensities of 769-P and 786-O cells, as evidenced by CCK8 and wound healing assays. Conclusion The NRS assumes a pivotal role in ascertaining the prognosis, tumor mutation burden, immunotherapy response, drug susceptibility, and immune cell infiltration features of ccRCC patients. SLC25A37 emerges as a putative player in immunosuppressive microenvironments, thereby providing a prospective avenue for the design of innovative immunotherapeutic targets for ccRCC.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38801430</pmid><doi>10.1007/s00432-024-05761-y</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1432-1335
ispartof Journal of cancer research and clinical oncology, 2024-05, Vol.150 (5), p.278-278, Article 278
issn 1432-1335
0171-5216
1432-1335
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11129999
source MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA/Free Journals; SpringerLink Journals - AutoHoldings
subjects Algorithms
Biomarkers, Tumor - genetics
Cancer Research
Carcinoma, Renal Cell - genetics
Carcinoma, Renal Cell - immunology
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - therapy
Cell Line, Tumor
Cell Proliferation
Clear cell-type renal cell carcinoma
Gene Expression Regulation, Neoplastic
Hematology
Humans
Immunotherapy
Immunotherapy - methods
Infiltration
Internal Medicine
Kidney cancer
Kidney Neoplasms - genetics
Kidney Neoplasms - immunology
Kidney Neoplasms - pathology
Medicine
Medicine & Public Health
Metastases
Metastasis
Microenvironments
Mutation
Necroptosis
Oncology
Prognosis
Sequence analysis
Tumor cells
Tumor Microenvironment - immunology
Tumors
Wound healing
title Prognostic impact and immunotherapeutic implications of NETosis-related prognostic model in clear cell renal cell carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T06%3A40%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20impact%20and%20immunotherapeutic%20implications%20of%20NETosis-related%20prognostic%20model%20in%20clear%20cell%20renal%20cell%20carcinoma&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Mao,%20Xingjun&rft.date=2024-05-27&rft.volume=150&rft.issue=5&rft.spage=278&rft.epage=278&rft.pages=278-278&rft.artnum=278&rft.issn=1432-1335&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-024-05761-y&rft_dat=%3Cproquest_pubme%3E3060564808%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3060564808&rft_id=info:pmid/38801430&rfr_iscdi=true